Across TCGA pan-cancer cohorts, MIR450B Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MIR450B data layer compared with 14 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher MIR450B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MIR450B expression acts as an unfavorable survival marker.

CHOL are the cancer types where MIR450B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	DFS	Median	All	0.045	0.486	.009	15	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: MIR450B tumor-vs-normal RNA expression · all MIR450B data types